Luzu (luliconazole) / Bausch Health 
Welcome,         Profile    Billing    Logout  
 7 Diseases   1 Trial   1 Trial   200 News 


«1234»
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  Luliconazole, a highly effective imidazole, against Fusarium species complexes. (Pubmed Central) -  May 15, 2021   
    Amphotericin B had a poor effect with a high MIC (64 µg/ml), followed by terbinafine (32 µg/ml), posaconazole (16 µg/ml), caspofungin (16 µg/ml), voriconazole (4 µg/ml), and itraconazole (4 µg/ml). Overall, our findings indicated that luliconazole has great activity against environmental and clinical Fusarium species complexes in comparison to tested antifungals.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  Investigating natural antibiofilm components: a new therapeutic perspective against candidal vulvovaginitis. (Pubmed Central) -  May 15, 2021   
    Henceforth, the current hypothesis narrates an investigational proposal for exploration and combination of naturally derived antibiofilm components with luliconazole (imidazole antifungal agent) as a new therapeutic paradigm against CVV...The effective disruption of a biofilm could further lower infection resistance and recurrence as well. In conclusion, the purported hypothesis could speed up the emergence of novel drug combinations and accelerates new product development with solid, synergistic, and complementary activities against C. albicans and its biofilm, making it amenable for generating pre-clinical and clinical results therebycreating a suitableroadmap for commercialization.
  • ||||||||||  Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health, Kerydin (tavaborole) / Pfizer
    Preclinical, Journal:  In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale. (Pubmed Central) -  Apr 7, 2021   
    Tavaborole showed no synergistic effect with terbinafine and was synergistically effective with itraconazole against 18.8% of the strains (3/16 strains). The results suggest that a combination of topical and oral drugs could be a potential clinical option for onychomycosis treatment, and overall, the efinaconazole and oral drug combination would be the most advantageous among the tested combinations.
  • ||||||||||  Januvia (sitagliptin) / Merck (MSD)
    Journal:  Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2. (Pubmed Central) -  Jan 5, 2021   
    Fragment-based scaffold analysis and R-group decomposition uncovered pyrrolidine and the indole molecular scaffolds as the potent fragments for designing and synthesizing the novel drug-like molecules for targeting SARS-CoV-2. This comprehensive and systematic assessment of small-molecule viral therapeutics' entire chemical space realised critical insights to potentially privileged scaffolds that could aid in enrichment and rapid discovery of efficacious antiviral drugs for COVID-19.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Clinical, Journal:  A review of neococcid scale insects (Hemiptera: Sternorrhyncha: Coccomorpha) based on the morphology of the adult males. (Pubmed Central) -  Oct 21, 2020   
    B; Luzulaspis caricis (Ehrhorn); Akermes scrobiculatus (Maskell); A. pingue (Maskell); Cardiococcus major (Maskell); Ctenochiton serratus Green; C. eucalypti Maskell, and ?Pulvinaria dodonaeae Maskell)...At least 1 illustration is included of an adult male of each of the taxa (mainly families) discussed here. Identification keys are provided for most of the males described to-date.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  Vaccine hesitancy in Spain (1801), Ruiz de Luzuriaga responses in defense of vaccination (Pubmed Central) -  Sep 27, 2020   
    It has been considered as an introducer, disseminator and ardent defender of the vaccine, as can be seen from the analysis of the bulky correspondence generated between 1801 and 1802 cataloged as "Papeles sobre la vacuna". These documents, preserved in the Academy library, show their activity as a propagator of the method and its capacity to respond to the doubts and concerns related to their possible adverse effects, avoiding jeopardizing the continuity of vaccines.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Clinical, Journal:  The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains. (Pubmed Central) -  Jun 6, 2020   
    50% and 27.8% of clinical and environmental isolates of A. flavus, were resistant to caspofungin, respectively. Whereas, all the isolates were found to be resistant to amphotericin B. The analysis of our data clearly indicated that luliconazole (with MIC 0.00244 μg/ml for clinical and 0.00336 μg/ml for environmental isolates) had the highest in vitro activity against A. flavus strains.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  The smut fungi of Greenland. (Pubmed Central) -  Mar 21, 2020   
    Thirteen species, Anthracoidea altera, A. capillaris, A. limosa, A. liroi, A. pseudofoetidae, A. scirpoideae, A. turfosa, Microbotryum lagerheimii, M. stellariae, Schizonella elynae, Stegocintractia luzulae, Urocystis fischeri, and U. tothii, are reported for the first time from Greenland...subfilifolia, is proposed for Kobresia filifolia subsp. subfilifolia.
  • ||||||||||  fluconazole / Generic mfg., Luzu (luliconazole) / Bausch Health
    Clinical, Journal:  The potency of luliconazole against clinical and environmental Aspergillus nigri complex. (Pubmed Central) -  Mar 10, 2020   
    Luliconazole versus amphotericin B, voriconazole, posaconazole and caspofungin is a potent antifungal for Aspergillus Nigri complex. The in vitro extremely antifungal efficacy against black Aspergillus strains of luliconazole, is different from those of other used antifungals.
  • ||||||||||  Jublia (efinaconazole) / Kaken, Bausch Health, Luzu (luliconazole) / Bausch Health
    Clinical, Journal:  Characteristics and Efficacy of Two Topical Therapeutic Agents for Onychomycosis. (Pubmed Central) -  Mar 2, 2020   
    Both efinaconazole 10% solution and luliconazole 5% solution have high antifungal activities for Trichophyton species. These two topical agents, therefore, have certainly increased treatment options for onychomycosis in the daily practice of dermatology.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  Herbal ethosomal gel containing luliconazole for productive relevance in the field of biomedicine. (Pubmed Central) -  Feb 27, 2020   
    In the end, it was estimated that ethosomal suspension and lyophilized ethosomal suspension was utmost stable at 4 °C/60 ± 5 RH. The complete study clearly indicates that the buildup of ethosomal formulation with luliconazole and neem extract show synergistic effect thereby, expressing excellent result against the treatment of fungal infection.
  • ||||||||||  Jublia (efinaconazole) / Kaken, Bausch Health, Astat (lanoconazole) / Maruho, Luzu (luliconazole) / Bausch Health
    Journal:  In Vitro Activities of 15 Antifungal Drugs against a Large Collection of Clinical Isolates of Microsporum canis. (Pubmed Central) -  Feb 25, 2020   
    FDA-approved antifungal drugs, that is luliconazole, efinaconazole and lanoconazole, showed the highest antifungal activity and should be promising candidates for the treatment of dermatophytosis caused by M canis. However, their therapeutic effectiveness remains to be determined in clinical settings.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  Distinct seasonal dynamics of responses to elevated CO in two understorey grass species differing in shade-tolerance. (Pubmed Central) -  Jan 16, 2020   
    While elevated [CO] stimulated photosynthesis in L. sylvatica mainly in the peak of the growing season (by 55%-57% in July and August), even at low light intensities (50 µmol m s), stimulatory effect of [CO] in C. arundinacea was found mainly under high light intensities (200 µmol m s) at the beginning of the growing season (increase by 171% in May) and gradually declined during the season. Elevated [CO] also substantially stimulated leaf mass area and root-to-shoot ratio in L. sylvatica, while only insignificant increases were observed in C. arundinacea.Our physiological and morphological analyses indicate that understorey species, differing in shade-tolerance, under elevated [CO] exploit distinct niches in light environment given by the dynamics of the tree canopy.
  • ||||||||||  fluconazole / Generic mfg., Spherazole (itraconazole) / RA Chem, JW Pharma, Spherics
    Journal:  High prevalence of itraconazole resistance among Candida parapsilosis isolated from Iran. (Pubmed Central) -  Dec 22, 2019   
    For the purpose of the study, the isolates were subjected to antifungal susceptibility testing against fluconazole (FLZ), itraconazole (ITZ), voriconazole (VRZ), and two new azole drugs, namely luliconazole (LUZU) and lanoconazole (LZN)...This may have been associated with the long-term ITZ prophylaxis/therapy in patients infected with candidiasis. Hence, the adoption of an appropriate antifungal agent is a crucial step for starting the treatment.
  • ||||||||||  Review, Journal:  Multiresistant Fusarium Pathogens on Plants and Humans: Solutions in (from) the Antifungal Pipeline? (Pubmed Central) -  Dec 12, 2019   
    ESCMID and ECMM joint guidelines, following the majority of published studies, suggest early therapy with amphotericin B and voriconazole, in conjunction with surgical debridement and reversal of immunosuppression...Recent studies present novel compounds that are effective against some pathogenic fungi including Fusarium. We discuss the robust and dynamic antifungal pipeline, including results from clinical trials as well as preclinical data that might appear beneficial for patients with invasive fusariosis.
  • ||||||||||  Luzu (luliconazole) / Bausch Health
    Journal:  Molecular Docking-Guided Ungual Drug-Delivery Design for Amelioration of Onychomycosis. (Pubmed Central) -  Aug 29, 2019   
    The present work envisaged an adherent luliconazole-loaded bilayer nail lacquer (BNL) with significant transungual activity...In Conclusion, it is deduced that the conventional treatment modalities for onychomycosis require circumvention of certain pharmacotechnical caveats. Therefore, in the present study, a multipronged BNL system was proposed, which negates the need of frequent drug application, improvises cosmetic appearance, yields fruitful therapeutic outcomes, and has a clinical supremacy over the available therapeutics.
  • ||||||||||  Sebifin (terbinafine HCL) / Generic Mfg.
    Journal:  Revival of favus in Japan caused by Trichophyton schoenleinii. (Pubmed Central) -  Aug 10, 2019   
    Pathogenic fungi were identified as T. schoenleinii by polymerase chain reaction-based DNA sequencing, targeting the internal transcribed spacer regions of the rRNA gene using the formalin-fixed, paraffin-embedded tissue sample. She was successfully treated with p.o. administration of terbinafine and topical application of luliconazole cream.
  • ||||||||||  lanoconazole (M1100) / Maruho, Luzu / Bausch Health
    Journal:  Potent Activity of Luliconazole, Lanoconazole and Eight Comparators against Molecularly Characterizedspecies. (Pubmed Central) -  Jun 22, 2019   
    Luliconazole and lanoconazole demonstrated very low GM MIC values of 0.005 μg/ml and 0.013 μg/ml, respectively, in comparison with 0.51 μg/ml for micafungin, 0.85 μg/ml for efinaconazole, 1.12 μg/ml for natamycin, 1.18 μg/ml for anidulafungin, 1.31 μg/ml for voriconazole, 1.35 μg/ml for caspofungin, 1.9 μg/ml for amphotericin B and 4.08 μg/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due tospecies.
  • ||||||||||  Jublia (efinaconazole) / Kaken, Bausch Health
    Preclinical, Journal:  In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators Against Dermatophyte Isolates. (Pubmed Central) -  Jun 22, 2019   
    The geometric mean MICs were the lowest for luliconazole (0.0005 μg/mL), followed by lanoconazole (0.002 μg/mL), efinaconazole (0.007 μg/mL), terbinafine (0.011 μg/mL), itraconazole (0.095 μg/mL) and fluconazole (12.77 μg/mL). It appears that efinaconazole, lanoconazole and luliconazole are promising candidates for the treatment of dermatophytosis due toand.
  • ||||||||||  fluconazole / generics, clotrimazole / generics, terbinafine HCL / generics
    Journal:  Mutation in the Squalene epoxidase gene ofandassociated with allylamine resistance. (Pubmed Central) -  Jun 22, 2019   
    ...Antifungal susceptibility testing of the isolated Trichophyton species (n = 127) was carried out with 12 antifungal agents: fluconazole, voriconazole, itraconazole, ketoconazole, sertaconazole, clotrimazole, terbinafine, naftifine, amorolfine, ciclopirox olamine, griseofulvin, and luliconazole...This transition leads to the substitution of amino acid phenylalanine to leucine in 397position of the squalene epoxidase enzyme. In homology modelling the mutant residue was smaller than wild type and positioned in the dominant site of squalene epoxidase during drug interaction, which may lead to failure to block ergosterol biosynthesis pathway by the antifungal drug.